1cP-LSD (1-cyclopropanoyl-LSD, also marketed under the name Curie) is a synthetic psychedelic of the lysergamide family and an acylated derivative of LSD featuring a cyclopropanoyl group at the N1 position of the lysergamide core. It is firmly established as a prodrug for LSD: the cyclopropanoyl ester is cleaved by plasma and tissue esterases following ingestion, releasing pharmacologically active LSD. Human pharmacokinetic studies and the broader body of prodrug research for 1-acyl lysergamides support this mechanism. The subjective effects of 1cP-LSD are therefore the full LSD experience, with a delayed onset attributable to the conversion step.
Community reports uniformly describe 1cP-LSD as producing effects indistinguishable from LSD at peak, with an onset typically in the 60–90 minute range and duration of 8–12 hours. First-time users often note the slightly longer come-up compared to blotter LSD but report that peak effects and overall character are LSD in every meaningful sense. Experience reports describe a deep, immersive experience of 1cP-LSD at 150 μg as "legal lysergamide — identical to LSD-25" with the onset simply being 60–75 minutes rather than the 30–45 minutes typical of LSD directly.
1cP-LSD became one of the more widely available and better-documented LSD prodrug analogs, with a larger community knowledge base than many other members of the series. It has been used across the full spectrum of lysergamide applications — single large doses for profound psychedelic experiences, moderate doses for recreational and exploratory use, and microdosing protocols for mood and cognitive enhancement. Community reports note broad positive experiences with first-time moderate doses, describing "deep conversations" and "real introspection" alongside visual richness.
Testing with Ehrlich reagent remains essential to rule out dangerous adulterants. The risk profile is identical to LSD given the prodrug mechanism, with all the same contraindications and harm reduction principles applying.
Safety at a Glance
High Risk- Equivalent microgram-per-microgram potency to LSD is assumed:
- Threshold: 15–25 μg
- Toxicity: Acute Toxicity Identical in expectation to LSD: extremely low. No pharmacological fatalities documented from 1cP-LSD....
- Overdose risk: Overdose 1cP-LSD has no known toxic dose. However, higher doses increase the risk of adverse psyc...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 8 hrs – 12 hrsHow It Feels
The tab is bitter only in your expectation; the actual taste is negligible. For the first forty minutes almost nothing happens, and impatience might tempt you to take more, but this would be a mistake. 1cP-LSD reveals itself on its own schedule. The first real signal is often emotional: a slight brightening of mood, a sense that the atmosphere in the room has become charged with potential. Then the walls begin to breathe.
The come-up unfolds in waves. Physical energy rises, settling into a vibrating alertness that concentrates in the chest and radiates outward. Your pupils dilate. Light seems to pour into the world from an extra source. Textures acquire a hyper-real definition, as though you have switched from standard to ultra-high-definition perception. Music gains dimensionality, revealing layers of production and intent that were previously flattened into a single stream. The mental landscape opens concurrently: thoughts accelerate and interconnect, ideas that normally live in separate compartments begin conversing freely.
The peak of 1cP-LSD is, to most who have experienced both, virtually indistinguishable from LSD itself. Surfaces flow with organic geometry, faces shift and morph with kaleidoscopic symmetry, and closed-eye visuals present elaborate cathedrals of light and form. Time becomes elastic, stretching minutes into apparent hours during moments of deep absorption. Emotionally the territory is wide and unpredictable: euphoria, awe, vulnerability, hilarity, and occasionally confrontation with difficult truths all share the stage. The body carries a characteristic tension in the jaw and shoulders, a persistent energy that wants to move.
The descent is long and layered. Visuals simplify gradually, the mental velocity slows, and eventually you find yourself in a state that is still perceptibly altered but no longer overwhelming. There is often a crystalline clarity in this afterglow period, a feeling that the world has been polished. Sleep typically remains out of reach for several hours after effects have nominally ended, but the residual wakefulness is contemplative and often deeply restful in its own way.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(20)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Increased salivation— Increased salivation (hypersalivation or sialorrhea) is the excessive production of saliva beyond wh...
- Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Physical fatigue— Physical fatigue is a state of bodily exhaustion characterized by reduced energy, diminished capacit...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stamina enhancement— Stamina enhancement is an increase in one's ability to sustain physical and mental exertion over ext...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(19)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Chromatic aberration— A visual distortion in which the colors reflected from object surfaces split into distinct, offset l...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- External hallucination— A visual hallucination that manifests within the external environment as though it were physically r...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Recursion— The visual field begins to repeat and nest within itself in a self-similar, fractal-like manner, as ...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(26)
- Addiction suppression— Addiction suppression is the experience of a marked decrease in or complete cessation of the craving...
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Ego replacement— Ego replacement is the experience of one's usual personality and sense of self being completely over...
- Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Personal meaning enhancement— Personal meaning enhancement is a state in which everyday events, coincidences, song lyrics, environ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Suggestibility enhancement— Heightened receptivity to external suggestions, ideas, and influence, commonly experienced during ps...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought disorganization— Thought disorganization is a cognitive impairment in which the normal capacity for structured, seque...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(4)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
Multi-sensory(3)
- Machinescapes— Machinescapes are complex multisensory hallucinations involving the perception of enormous mechanica...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(4)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Spirituality enhancement— A profound intensification of spiritual feelings, mystical awareness, and a sense of sacred connecti...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
1cP-LSD acts as a prodrug for LSD. The cyclopropanoyl group at N1 is cleaved by esterase enzymes — primarily in plasma and intestinal tissue — releasing LSD, which then exerts full LSD pharmacology. LSD is a biased partial agonist at serotonin 5-HT2A receptors preferentially activating β-arrestin over Gq signaling pathways, producing its characteristic disruption of thalamocortical predictive-coding networks and increased cortical glutamate release. The result is the hallmark LSD experience: expanded perceptual field, enhanced associative cognition, emotional amplification, and at higher doses, ego dissolution.
The cyclopropanoyl moiety (a 3-membered ring acyl group) is notable for its compact geometry and moderate hydrophobicity, which may influence the rate of esterase hydrolysis relative to simpler acyl groups like propionyl (1P-LSD). The conversion efficiency and rate have not been formally quantified for 1cP-LSD specifically, but experience reports are consistent with efficient conversion.
Receptor Targets (via LSD)
- 5-HT2A receptors — principal target; partial agonist; cortical 5-HT2A activation is necessary and sufficient for classical psychedelic effects
- 5-HT1A receptors — partial agonist; modulates emotional tone and introspective quality
- 5-HT2C receptors — agonist; contributes to potential anxiety at high doses
- Dopamine D2/D3 receptors — moderate affinity; "dopaminergic edge" of LSD; stimulation, emotional intensification
- α-adrenergic receptors — tachycardia, mydriasis, vasoconstriction
- Histamine H1 — mild sedation at low doses
Pharmacokinetics
Community-reported onset of 60–90 minutes is consistent with an interposed conversion step. Peak plasma LSD concentrations would be expected at approximately 1.5–3 hours after ingestion of 1cP-LSD. Duration of 8–12 hours matches LSD. No formal human PK data exist for 1cP-LSD itself.
Tolerance
Identical to LSD: rapid functional tolerance within 24–48 hours, full cross-tolerance with all serotonergic psychedelics, reversal over 5–7 days.
Detection Methods
Urine Detection
1cP-LSD and its metabolites are not targeted by standard immunoassay-based urine drug screens. Because lysergamides are active at microgram doses, the absolute quantity of drug and metabolite present in biological samples is extremely low, making detection inherently difficult. Specialized urine assays using liquid chromatography-tandem mass spectrometry (LC-MS/MS) can identify lysergamide metabolites within approximately 24 to 72 hours after ingestion, though this window is shorter than most other drug classes due to rapid metabolism and renal clearance.
Blood and Serum Detection
Blood detection windows for 1cP-LSD are narrow. Plasma concentrations peak within 1 to 3 hours of oral administration and fall below detectable thresholds within 6 to 12 hours for most analytical methods. LC-MS/MS can extend this window modestly, but serum testing for lysergamides is rarely performed outside of forensic or research contexts due to the specialized equipment required and the very low concentrations involved.
Standard Drug Panel Inclusion
1cP-LSD is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. These panels test for amphetamines, cannabinoids, cocaine metabolites, opiates, and PCP (with extended panels adding benzodiazepines, barbiturates, and similar classes). Lysergamides do not cross-react with any of these immunoassay targets. Detection requires a specific request for lysergamide testing, which is uncommon in workplace, probationary, or emergency department screening.
Confirmatory Methods
When lysergamide use is specifically suspected, confirmatory testing relies on LC-MS/MS or gas chromatography-mass spectrometry (GC-MS). LC-MS/MS is the preferred method due to its superior sensitivity at picogram-per-milliliter concentrations. Immunoassay-based LSD-specific screens exist but suffer from high false-negative rates with novel lysergamide analogs, as antibody cross-reactivity varies between compounds.
Reagent Testing (Harm Reduction)
For harm reduction identification, the Ehrlich reagent is the primary tool for 1cP-LSD. A small sample placed on the reagent should produce a purple to violet color change, indicating the presence of an indole moiety characteristic of lysergamides. The Hofmann reagent provides a confirmatory blue to purple reaction. Importantly, the Marquis reagent shows no reaction or a faint olive discoloration with lysergamides, which helps distinguish them from other compound classes. A positive Ehrlich result does not confirm the specific lysergamide identity but does rule out NBOMe and NBOH compounds, which show no Ehrlich reaction. Using both Ehrlich and Hofmann reagents together provides greater confidence in lysergamide identification.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
History
Market Emergence
1cP-LSD (1-cyclopropanoyl-d-lysergic acid diethylamide) appeared on the research chemical market around 2019, emerging as a direct response to Germany's Neue-psychoaktive-Stoffe-Gesetz (NpSG), which had captured 1P-LSD under its generic structural definitions. The cyclopropanoyl modification — replacing the propionyl group of 1P-LSD with a cyclopropanecarbonyl group — was designed to fall outside the NpSG's structural coverage while retaining prodrug functionality .
Scientific Characterization
Brandt et al. (2020) published the analytical and behavioral characterization of 1cP-LSD as "Return of the lysergamides. Part VI" in Drug Testing and Analysis. The study demonstrated that 1cP-LSD induces the head-twitch response in C57BL/6J mice with an ED50 of 430.0 nmol/kg, comparable to 1P-LSD (ED50 = 349.6 nmol/kg). Incubation with human serum produced LSD as a metabolite, confirming the prodrug mechanism .
Germany subsequently extended NpSG coverage to include 1cP-LSD by early 2021, prompting yet another round of structural innovation in the research chemical market — with compounds like 1V-LSD (1-valeroyl-LSD) emerging as successors in the ongoing regulatory cat-and-mouse game .
References
- Brandt SD, Kavanagh PV, Westphal F, et al. Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD). Drug Test Anal. 2020;12(6):812-826.
- Chemical Collective. "1V-LSD — Introducing a new legal LSD prodrug for Germany." 2021.
Harm Reduction
Testing
Ehrlich reagent: purple/violet reaction confirms indole compound. As with all LSD prodrugs, a positive Ehrlich confirms the lysergamide class but does not distinguish 1cP-LSD from LSD or other analogs.
Dosing
Equivalent microgram-per-microgram potency to LSD is assumed:
- Threshold: 15–25 μg
- Light: 25–75 μg
- Common: 75–150 μg
- Strong: 150–300 μg
The delayed onset (60–90 minutes) is the most practically important difference from LSD. Do not redose during this window — community reports specifically highlight this risk for 1cP-LSD as a prodrug.
Set and Setting
- Stable emotional state; familiar, comfortable, safe environment
- Avoid use during acute mental health crises
- Trip sitter for first experiences or doses above 100 μg
- Plan the full day and following day — sleep quality after lysergamide use is poor, and integration takes time
Dangerous Combinations
- Lithium — Do not combine; seizures and cardiac events documented with lysergamides
- MAOIs — Serotonin syndrome
- Tramadol — Seizure risk
- Cannabis — Unpredictable amplification; frequently implicated in adverse outcomes
- Stimulants — Cardiovascular and psychological intensity amplification
Emergency Protocol
- Difficult experience: environment change, grounding techniques, calm presence of trusted person
- Benzodiazepines (diazepam 10–20 mg or equivalent) — reliable, safe reduction of LSD intensity
- Emergency services for physical safety concerns; report substance
Toxicity & Safety
Acute Toxicity
Identical in expectation to LSD: extremely low. No pharmacological fatalities documented from 1cP-LSD. All of LSD's acute toxicity data apply by prodrug reasoning.
Cardiovascular Effects
LSD-identical: mild tachycardia, blood pressure elevation, mydriasis, and peripheral vasoconstriction. Well tolerated in healthy individuals. Contraindicated with cardiac disease, arrhythmias, or severe hypertension.
Psychological Risks
- Acute panic and anxiety — Most common adverse event; risk scales with dose, unresolved psychological stress, and co-use of stimulants or cannabis
- Psychosis induction — Absolute contraindication with history of schizophrenia or bipolar I disorder
- HPPD — Persistent visual phenomena; documented in community reports following 1cP-LSD use
- Difficult integration — High-dose experiences, especially involving ego dissolution, may require psychological support
Contraindications
- Personal or family history of schizophrenia, schizoaffective disorder, or bipolar I disorder
- Lithium, MAOI, antipsychotic, or tramadol use
- Cardiovascular disease or uncontrolled hypertension
Overdose
No documented pharmacological overdoses. Extreme psychological distress is the expected presentation at high doses. Standard benzodiazepine intervention applies.
Addiction Potential
non-addictive with a low abuse potential
Overdose Information
Overdose
1cP-LSD has no known toxic dose. However, higher doses increase the risk of adverse psychological reactions. These reactions include anxiety, delusions and panic attacks. Medical attention is usually not needed except in the case of severe psychotic episodes or the ingestion of fake acid (such as 25i-NBOMe or DOB). Administration of benzodiazepines or antipsychotics can help to relieve the acute negative cognitive effects of 1cP-LSD.
Although no formal studies have been conducted, it is assumed that like LSD itself, 1cP-non-addictive with a low abuse potential. There are no literature reports of successful attempts to train animals to self-administer LSD — an animal model predictive of abuse liability — indicating that it does not have the necessary pharmacology to either initiate or maintain dependence.
Germany: 1cP-LSD is controlled under the NpSG (New Psychoactive Substances Act) as of July 2, 2021. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Japan: 1cP-LSD is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.
Sweden: Sweden's public health agency suggested classifying 1cP-LSD as a dangerous substance on December 18, 2019.
Turkey:** 1cP-LSD is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: 1cP-LSD is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26, 2016.
Responsible use
Research chemicals
Psychedelics
LSD
1cP-LSD (Wikipedia)
1-CPA-LSD (Isomer Design)
APA formatted reference
Please see the citation formatting guide if you need assistance properly formatting citations. -->
Tolerance
| Full | almost immediately after ingestion |
| Half | 5-7 days |
| Zero | 14 days |
Cross-tolerances
Legal Status
Canada: 1cP- LSD is unscheduled in Canada.
Czech Republic: 1cP-LSD is not a controlled substance, and is not named on the list of illegal substances.
Germany: 1cP-LSD is controlled under the NpSG (New Psychoactive Substances Act) as of July 2, 2021. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Japan: 1cP-LSD is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.
Sweden: Sweden's public health agency suggested classifying 1cP-LSD as a dangerous substance on December 18, 2019.
Turkey:** 1cP-LSD is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: 1cP-LSD is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26, 2016.
Responsible use
Research chemicals
Psychedelics
LSD
1cP-LSD (Wikipedia)
1-CPA-LSD (Isomer Design)
APA formatted reference
Please see the citation formatting guide if you need assistance properly formatting citations. -->
Experience Reports (1)
Tips (3)
Clear your schedule for the full duration of 1cP-LSD plus afterglow. Do not plan any obligations, driving, or important decisions for the day. Having a time pressure or commitment hanging over you adds unnecessary anxiety.
Use a milligram scale to weigh 1cP-LSD if it comes as a powder. Eyeballing doses of potent psychedelics is irresponsible. A quality 0.001g scale costs under $30 and could prevent a seriously overwhelming experience.
Do not combine 1cP-LSD with lithium (seizure risk), tramadol (seizure/serotonin syndrome risk), or cannabis at higher doses unless very experienced. Cannabis dramatically intensifies and can destabilize a psychedelic experience.
See Also
Similar by Effects
Same Class
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 1cP-LSD - TripSit Factsheet
TripSit factsheet for 1cP-LSD
tripsit - 1cP-LSD - Wikipedia
Wikipedia article on 1cP-LSD
wikipedia